Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel

Keyphrases

• Israel 100%
• Metastatic Non-small Cell Lung Cancer 100%
• Test Pattern 100%
• Tumor Proportion Score 100%
• PD-L1 Testing 100%
• Tumor 33%
• Health Care Services 33%
• Monotherapy 33%
• Aberrations 33%
• Adherence to Guidelines 33%
• Maccabi Healthcare Services 33%
• Newly Diagnosed 33%
• High Adherence 33%
• Adenocarcinoma 33%
• National Cancer Registry 33%
• Brain Metastases 33%
• January 2017 33%
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) 33%
• Former Smokers 33%
• Programmed Death-ligand 1 (PD-L1) 33%
• State Mandates 33%
• Treatment Patterns 33%
• Non-small Cell Lung Cancer Patients 33%
• EGFR mutation 33%
• PD-L1 Inhibitor 33%
• ROS1 33%
• PD-L1 Expression 33%
• Stage IV Non-small Cell Lung Cancer 33%
• Systemic Anti-cancer Treatment 33%
• Platinum Doublets 33%

Medicine and Dentistry

• Neoplasm 100%
• Non Small Cell Lung Cancer 100%
• Programmed Death-Ligand 1 100%
• Health Service 25%
• Monotherapy 25%
• Oncology 25%
• Smoking 25%
• Adenocarcinoma 25%
• Epidermal Growth Factor Receptor 25%
• Cancer Registry 25%
• Brain Metastasis 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Neoplasm 100%
• Non Small Cell Lung Cancer 100%
• Monotherapy 25%
• Adenocarcinoma 25%
• Epidermal Growth Factor Receptor 25%
• Cancer Registry 25%
• Brain Metastasis 25%